港股異動 | 百威亞太漲4.7%再創新高 機構看高公司股價至34港元
格隆匯10月8日丨百威亞太(1876.HK)延續近期強勢再度上行,現報31.95港元,漲幅4.75%,暫成交12.1億港元,最新總市值4231.3億港元。中信證券指,看好公司在啤酒市場高端化趨勢下的綜合競爭力,有望持續夯實亞洲龍頭地位、保持穩健較高增長。預計2019-2021年EPS為0.08、0.10、0.12美元(摺合0.63、0.77、0.97港元),給予公司2020年EV/EBITDA估值22倍,對應目標價34港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.